Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors

Pharmacy World and Science

Volumn 20, Issue 4, 1998, Pages 161-172

  Herben, Virginie M M ^a   Ten Bokkel Huinink, Wim W ^b   Schellens, Jan H M ^b   Beijnen, Jos H ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Camptothecin; Clinical pharmacokinetics; Irinotecan; Topoisomerase I inhibitors; Topotecan

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EXATECAN; GRANISETRON; IFOSFAMIDE; IRINOTECAN; LOPERAMIDE; LURTOTECAN; ONDANSETRON; PHENOBARBITAL; PHENYTOIN; RUBITECAN; TOPOTECAN; UNCLASSIFIED DRUG; VALPROIC ACID; VINCRISTINE;

BIOAVAILABILITY; COLORECTAL CANCER; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG STABILITY; HUMAN; LUNG CANCER; OVARY CANCER; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMA CLEARANCE; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; HUMANS; TOPOTECAN;

EID: 0031823914     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008613806051     Document Type: Review

References (110)

1. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumour inhibitor from Camptotheca acuminata. J Am Chem Soc 1966;88:3888-90.
2. Govindachari TR, Visnawathan N. Alkaloids of Mappia foedita. Phytochemistry 1972;11:3529-31.
3. Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB. Preliminary pharmacologic and clinical evaluation of camptothecin sodium. Ca-ncer Chemother Rep 1970;54:461-70.
4. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972;56:95-7.
5. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS. Phase I clinical trial of weekly and daily treatment with camptothecin: correlation with preclinical studies. Cancer Chemother Rep 1972;56:515-21.
6. Hsiang Y-H, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-5.
7. Hsiang Y-H, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;48:1722-6.
8. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994;86:836-42.
9. Natelson EA, Giovanella BC, Verschraegen CF, Fehir KM, De Ipolyi PD, Harris N, Stehlin JS. Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitro- camptothecin as anticancer agents. Ann NY Acad Sci 1996;803:224-30.
10. Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997;8:837-55.
11. Carmichael J, Ozols RF. Topotecan, an active new antineo- plastic agent: review and current status. Exp Opin Invest Drugs 1997;6:593-608.
12. O'Reilly S, Rowinsky EK. The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996. Crit Rev Oncol/Hematol 1996;24:47-70.
13. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y. Structure- activity study of the actions of camptothecin derivatives on mammalian topoisomerase I. Evidence of a specific receptor site and for a relation to antitumor activity. Cancer Res 1989;49:1465-9.
14. Hsiang Y-H, Liu LF, Wall ME, et al. DNA topoisomerase I- mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res 1989;49:4385-9.
15. Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989;32:715-20.
16. Pommier Y, Jaxel C, Kerrigan D, Kohn KW. Structure-activity relationship of topoisomerase I inhibition by camptothecin derivatives: Evidence for the existence of a ternary complex. In: Potmesil M, Kohn KW, eds. DNA topoisomerases in cancer. New York: Oxford University Press, 1991:121-32.
17. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoismerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989;49:5077-82.
18. Burris III HA, Hanauske AR, Johnson RK, Marshall MH, Kuhn JG, Hilsenbeck SG, Von Hoff DD. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units. J Natl Cancer Inst 1992;84:1816-20.
19. Supko JG, Plowman J, Dyker DJ, Zaharko DS. Relationship between the schedule dependence of 9-amino-20(S)-camptothecin (AC; NSC 603071) antitumor activity in mice and its plasma pharmacokinetics. Proc Am Ass Cancer Res 1992;33:432.
20. Underberg WJM, Goossen RMJ, Smith BR. Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution. J Pharm Biomed Anal 1990;8:681-3.
21. Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sc 1992;81:676-84.
22. Burke TG, Munshi CB, Mi Z. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J Pharm Sci 1995;84:518-9.
23. Beijnen JH, Smith BR, Keijer WJ, Van Gijn R, Ten Bokkel Huinink WW, Vlasveld LTh, et al. High-performance liquid Chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. J Pharm Biomed Anal 1990;8:789-94.
24. Rosing H, Doyle E, Davies BE, Beijnen JH. High-performance liquid Chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. J Chrom B 1995;668:107-11.
25. Supko JG, Malspeis L. Liquid Chromatographic analysis of 9- aminocamptothecin in plasma monitored by fluorescence induced upon postcolumn acidification. J Liq Chrom 1992;15:3261-83.
26. Rivory LP, Robert J. Reversed-phase high-performance liquid Chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J Chrom B 1994;661:133-41.
27. Van Warmerdam LJC, Creemers GJ, Rodenhuis S, Rosing H, De Boer-Dennert M, Schellens JHM, etal. Pharmacokinetics and pharmacodynamics of topotecan administered at a daily times five schedule in phase II clinical trials using a limited sampling procedure. Cancer Chemother Pharmacol 1996;38:254-60.
28. Ten Bokkel Huinink WW, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;16:2183-93.
29. Ardizzoni A, Hansen HH, Dombernowsky P, Kaplan S, Postmus PE, Gamucci T, et al. Phase II study of topotecan in refractory and sensitive small cell lung cancer (SCLC). Eur J Cancer 1995;31A:S19.
30. Schiller JH, Von Pawel J, Clarke P, et al. Preliminary results of a reandomized phase II trial of topotecan (T) versus CAV as second-line therapy of small-cell lung cancer (SCLC). 8th World Conference on Lung Cancer, Dublin, Ireland. Lung Cancer 1997;18:13.
31. Saltz L, Sirott M, Young C, Tong W, Niedzwiecki D, Tzy-Jyun Y, et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 1993;85:1499-1507.
32. Verweij J, Lund B, Beijnen J, Planting A, De Boer-Dennert M, Koier I, et al. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 1993;4:673-8.
33. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994;12:553-9.
34. Oostweegel LMM, Van Warmerdam LJC, Schot M, Dubbelman AC, Ten Bokkel Huinink WW, Beijnen JH. Extravasation of topotecan, a report of two cases. J Oncol Pharm Pract 1997;3:115-6.
35. Herben VMM, Ten Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996;31:85-102.
36. Wall JG, Burris HA III, Von Hoff DD, Rodrigues G, Kneuper-Hall R, Shaffer D, et al. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs 1992;3:337-45.
37. Van Warmerdam LJC, Verweij J, Schellens JHM, Rosing H, Davies BE, De Boer-Dennert M, et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 1995;35:237-45.
38. Munshi CB, Mi Z, Burke TG. The biophysics underlying the favorable stability of the topotecan anticancer drug in human blood. Proc Am Ass Cancer Res 1995;36:444.
39. Cole DE, Blaney SM, Balis FM. Topotecan in physiologic fluids: depot of active drug in red blood cells. Proc Am Ass Cancer Res 1995;36:363.
40. Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A, Stewart CF. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol 1996;37:195-202.
41. Van Warmerdam LJC, Rosing H, Ten Bokkel Huinink WW, Maes RAA, Beijnen JH. Do topotecan concentrations in saliva reflect plasma concentrations? J Oncol Pharm Practice 1995;1:41-5.
42. Herben VMM, Ten Bokkel Huinink WW, Dubbelman AC, Mandjes IAM, Groot Y, Van Zomeren DM, Beijnen JH. Phase I and pharmacologic study of sequential intravenous topotecan and oral etoposide. Br J Cancer 1997;76:1500-8.
43. Schellens JHM, Creemers GJ, Beijnen JH, Rosing H, De Boer- Dennert M, McDonald M, et al. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 1996;73:1268-71.
44. Gerrits CJH, Burris H, Schellens JHM, Planting AST, Van der Burg MEL, Rodrigues GI, et al. Five days of oral topotecan (Hycamtin®), a phase I and pharmacologic study in adult patients with solid tumors. Submitted for publication.
45. Anonymous. Prescribing information HycamtinJ, SmithKline Beecham 1997.
46. Borkowski JM, Duerr M, Donehower RC, Rowinsky EK, Chen T-L, Ettinger DS, et al. Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol 1994;33:493-6.
47. O'Reilly S, Rowinsky EK, Slichenmyer W, Donehower RC, Forastiere AA, Ettinger DS, et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996;14:3062-73.
48. O'Reilly S, Rowinsky EK, Slichenmyer W, Donehower RC, Forastiere AA, Ettinger DS, et al. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J Natl Cancer Inst 1996;88:817-24.
49. Anonymous. Hycamtin, topotecan for the management of advanced ovarian cancer. Product monograph, SmithKline Beecham Pharmaceuticals 1996.
50. Zamboni WC, Gajjar AJ, Heideman RL, Beijnen JH, Rosing H, Houghton PJ, et al. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 1998, in press.
51. Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen T- L, Peereboom D, et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 1996;14:3074-84.
52. Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL, et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 1992;20:706-13.
53. Haas NB, La Creta FP, Walczak J, Hudes GR, Brennan JM, Ozols RF, O'Dwyer PJ. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res 1994;54:1220-6.
54. Bissery MC, Mathieu-Boué A, Lavelle F. Experimental antitumor activity of CPT-11 in vitro and in vivo. Ann Oncol 1992;3(suppl 1):82.
55. Rougier P, Bugat R, Douillard JY, Culine S, Sue E, Brunet P, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997;15:251-60.
56. Shimada Y, Yashino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993;11:909-13.
57. Rothenberg ML, Eckardt JR, Kuhn JG, Burris III HA, Nelson J, Hilsenbeck SG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14:1128-35.
58. Pilot HC, Wender DB, O'Connell MJ, Schroeder G, Goldberg RM, Rubin J, et al. Phase II trial of irinotecan in patients with metastatic coloreclal cancer. J Clin Oncol 1997;15:2910-9.
59. Abigerges D, Chabot GG, Armand J-P, Hérait P, Gouyette A, Gandia D, Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995;13:210-21.
60. De Forni M, Bugat R, Chabot GG, Culine S, Extra J-M, Gouyette A, et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan administered on a weeky schedule in cancer patients. Cancer Res 1994;54:4347-54.
61. Rothenberg ML, Kuhn JG, Burris III HA, Nelson J, Eckardt JR, Tristan-Morales M, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993;11:2194-204.
62. Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen T-L, et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994;54:427-36.
63. Sasaki Y, Yoshida Y, Sudoh K, Hakusui H, Fujii H, Ohtsu T, et al. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn J Cancer Res 1995;86:111-6.
64. Rivory PL, Chatelut E, Canal P, Mathieu-Boué A, Robert J. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res 1994;54:6330-3.
65. Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra J-M, et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 1995;6:141-51.
66. Herben V, Schellens J, Swart M, Gruia G, Beijnen J, Ten Bokkel Huinink WW. Phase I and pharmacokinetic (PK) study of irinotecan (CPT11) with a prolonged (14 D) infusion schedule. Proc Am Soc Clin Oncol 1997;16:201a.
67. Zamboni WC, Crom WR, Houghton PJ, Thompson JD, Stewart CF. Plasma protein binding of SN-38: the active metabolite of irinotecan. Pharmacotherapy 1996;16:500.
68. Takahashi T, Fujiwara Y, Sumiyoshi H, Miyazaki M, Elisna S, Oguri T, et al. Salivary drug monitoring of irinotecan (CPT- 11 and its active metabolite (SN-38) in cancer patients. Cancer Chemother Pharmacol 1997;40:449-52.
69. Lokiec F, Canal P, Gay C, Chatelut E, Armand J-P, Roché H, Bugat R, Gonçalvès E, Mathieu-Boué A. Pharmacokinetics of irinotecan and its metabolites in human blood, bile and urine. Cancer Chemother Pharmacol 1995;36:79-82.
70. Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T, Tsuru, D. CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobio-Dyn 1991;14:341-9.
71. Rivory PL, Robert J. Identification and kinetics of a ß-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 1995;36:176-9.
72. Iyer L, King C, Tephly T, Ratain MJ. UGT isoform 1.1 (UGT*1.1) glucuronidates SN-38, the active metabolite of irinotecan. Proc Am Soc Clin Oncol 1997;16:201a.
73. Canal P, Gay C, C, Dezeuze A, Douillard JY, Bugat R, Brunet R, et al. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 1996;14:2688-95.
74. Kaneda N, Nagata H, Furuta T, and Yokokura T. Metabolism and pharmacokinetics of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 1991;21:1159-69.
75. Rivory LP, Riou JF, Haaz MC, Sable S, Vuilhorgne M, Commerçon A, et al. Identification and properties of a major plasma metabolite of irinotecan (CPT-11 ) isolated from the plasma of patients. Cancer Res 1996;56:3689-94.
76. Lokiec F, Monegier du Sorbier B, Sanderink GJ. Irinotecan (CPT-11) metabolites in human bile and urine. Clin Cancer Res 1996;2:1943-9.
77. Rivory LP, Haaz M-C, Canal P, Lokiec F, Armand J-P, Robert J. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res 1997;3;1261-6.
78. Wasserman E, Myara A, Lokiec F, Goldwasser F, Trivin F, Mahjoubi M, et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997;8:1049-51.
79. Schaaf L, Ichhpurani N, Elfring G, Wolf D, Rothenberg M, Von Hoff D. Influence of age on the pharmacokinetics of irinotecan (CPT-11) and its metabolites, SN-38 and SN-38 glucuronide (SN-38G), in patients with prevously treated colorectal cancer. Proc Am Soc Clin Oncol 1997;16:202a.
80. Ratain MJ, Mick R, Gupta E, Lestingi TM, Schilsky RL, Vokes EE. Prospective evaluation of the effect of race and gender on irinotecan (CPT-11) pharmacokinetics and intestinal toxicity. Proc Am Soc Clin Oncol 1996;15:472.
81. Rivory LP, Bowles MR, Robert J, Pond SM. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10- hydroxycamptothecin (SN-38) by human liver carboxylesterase. Biochem Pharmacol 1996;52:1103-11.
82. Haaz MC, Rivory LP, Riché C, Vernillet L, Robert J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P-450 3A and drug interactions. Cancer Res 1998;58:468-72.
83. Gupta E, Wang X, Ramirez J, Ratain MJ. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol 1997;39:440-4.
84. Gupta E, Mick R, Ramirez J, Wang X, Lestingi TM, Vokes EE, Ratain MJ. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997;15:1502-10.
85. Fagbemi S, Iyer L, Mani S, Vogelzang NJ, Cohn H, Fasanmade A, Ratain MJ. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered with cyclosporine A. Proc Am Soc Clin Oncol 1997;16:219a.
86. Sasaki Y, Ohtsu A, Shimada Y, Ono K, Saijo N. Simultaneous administration of CPT-11 and fluoruracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer [letter]. J Natl Cancer Inst 1994;86:1096-8.
87. Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996;14:2959-67.
88. Lokiec F, Wasserman E, Santoni J, Mahjoubi M, Misset JL Cvitkovic E. Pharmacokinetics of the irinotecan/oxaliplatin combination: preliminary data of an ongoing phase I trial. Proc Am Soc Clin Oncol 1997;16:203a.
89. Sasaki Y, Hakusui, Mizuno S, Morita M, Miya T, Eguchi K, et al. A pharmacokinetic and pharmacodynamic analyis of CPT-11 and its active metabolite SN-38. Jpn J Cancer Res 1995;86:101-10.
90. Kudoh S, Fukuoka M, Masuda N, Yoshikawa A, Kusunoki Y, Matsui K, et al. Relationship between the pharmacokinetics of irinotecan and diarrhoea duing combination chemotherapy with cisplatin. Jpn J Cancer Res 1995;86:406-13.
91. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994;54:3723-5.
92. Gerrits CJ, Creemers GJ, Schellens JH, Wissel P, Planting AS, Kunka R, et al. Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x5 intravenous administration. Br J Cancer 1996;73:744-50.
93. O'Dwyer P, Cassidy J, Kunka R, Pas-Arez L, Kaye S, DePee S, et al. Phase I trial of GG211, a new topoisomerase inhibitor, using a 72 hour continuous infusion. Proc Am Soc Clin Oncol 1995;14:471.
94. Wanders J. The experience of the EORTC early clinical trials group (ECSG) with GW211 in solid tumors. The Eighth Conference on DNA Topoisomerases in Therapy, Amsterdam, 15-17 October 1997;72.
95. Schellens JHM, Pritchard JF, Gerrits CJH, Wissel PS, Beranek P, Creemers GJ, et al. Absolute oral bioavailability of the topoisomerase I inhibitor GG211. The Sixth Conference on DNA Topoisomerases in Therapy, Amsterdam, 6-8 September 1995;87.
96. Rubin E, Wood V, Bharti A, Trites D, Lynch C, Hurwitz S, et al. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1995;1:269-76.
97. Dahut W, Harold N, Takimoto C, Allegra C, Chen A, Hamilton M, et al. Phase I and pharmacologic study of 9- aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 1996;14:1236-44.
98. Takimoto CH, Dahut W, Marino MT, Nakashima H, Liang MD, Harold N, et al. Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. J Clin Oncol 1997;15(4):1492-501.
99. Liang MD, Dahut W, Quinn MF, Harold N, Arbuck SG, Chen A, et al. Preclinical and clinical studies of a new colloidal dispersion formulation of 9-aminocamptothecin. Proc Am Ass Cancer Res 1996;37:432.
100. Mani S, Iyer L, Janisch L, Wang X, Fleming GF, Schilsky RL, Ratain MJ. Phase I clinical and pharmacokinetic (PK) study of oral 9-aminocamptothecin (9-AC) (NSC-603071). Proc Am Soc Clin Oncol 1997;16:201a.
101. Sparreboom A, Stoter G, Loos WJ, Nooter K, Punt CJA, Colajori E, Verweij J. Oral bioavailability of 9-aminocamptothecin in adult patients with solid tumors. Proc Am Ass Cancer Res 1997;38:75.
102. Minami H, Mick R, Vokes EE, Ratain MJ. Pharmacodynamic models for leukopenia and thrombocytopenia of 9-aminocamptothecin. Proc Am Soc Clin Oncol 1996;15:179.
103. Grossman SA, Hochberg F, Fisher J, Chen TL, Kim L, Gregory R, et al. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. Proc Am Soc Clin Oncol 1997;16:389a.
104. Hinz HR, Harris NJ, Natelson EA, Giovanella BC. Pharmacokinetics of the in vivo and in vitro conversion of 9- nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs and mice. Cancer Res 1994;34:3096-100.
105. Verschraegen CF, Natelson E, Giovanella BC, Kavanagh JJ, Kudelka AP, Freedman RS, et al. A phase I and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anti-Cancer Drugs 1998;9:36- 44.
106. Verschraegen CF, Harris N, Steger M, Kavanagh J, Kudelka A, Giovanella B. Pharmacology study of multiple oral doses of 9-nitrocamptothecin (9NC). Proc Am Ass Cancer Res 1997;38:74.
107. Verschraegen CF, Giovanella BC, Harris N, Natelson E, Kavanagh JJ, Kudelka AP, et al. Pharmacodynamics and in vivo serum concentrations of the total drug and the lactone form of 9-nitrocamptothecin (9-NC) administered orally. Proc Am Ass Cancer Res 1996;37:180.
108. Toppmeyer D, Gupta E, Saleem A, Zamek R, Much J, Ibrahim J, et al. A phase I pharmacokinetic and pharmacodynamic study of camptothecin (CPT) and etoposide (E) in patients with advanced malignancies. Proc Am Soc Clin Oncol 1997;16:203a.
109. Gupta E, Ahmad FY, Cook TJ, Saleem A, Li X-G, Zamek R, et al. Optimizing administration of oral camptothecins: intestinal permeability of lactone and total 20(S) camptothecin (CPT). Proc Am Soc Clin Oncol 1997;16:237a.
110. Takiguchi S, Kumazawa E, Shimazoe T, Tohgo A, Kono A. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice. Jpn J Cancer Res 1997;88:760-9.